The certification attests that the company operates in accordance with Brazilian GMP guidelines, which align with the World Health Organisation’s recommendations, the company said in an exchange filing.
The certification specifically covers the production of the active pharmaceutical ingredient (API) metformin hydrochloride, which is used to treat diabetes mellitus.
Wanbury’s certified facility is located at A-15, MIDC Industrial Area, Patalganga, in the Raigad district of Maharashtra. The certification is valid until May 12, 2027, and includes a clause stating that it may be revoked should the company fail to comply with current GMP standards.
On May 12, Wanbury said it had informed of the approval and certificate from ANVISA, Brazil for its Tanuku site in Andhra Pradesh as well.
In September 2024, the company was granted a certificate of suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for its active pharmaceutical ingredient (API), Dextromethorphan. This API, widely used as an antitussive, serves as a key component in cough suppressant medications.
Wanbury Ltd reported a total income of ₹173.84 crore for the quarter ended March 31, 2025 (Q4FY25), compared to ₹140.33 crore in the same period a year ago. The company posted a net profit of ₹20.25 crore in Q4 FY25, down from ₹33.63 crore reported in the corresponding quarter of the previous financial year.
Wanbury shares were trading 3.82% lower at ₹292.62 apiece at 12 pm. The stock has gained 37% in the last six months.
Also Read: Bonus Alert: 14 lakh small shareholders of this CV producer set to get free shares after 14 years
